Travere Therapeutics Inc (TVTX)

Apr 21, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by Invesco Ltd. - Defense World

Apr 21, 2025

Apr 19, 2025

How to Take Advantage of moves in (TVTX) - news.stocktradersdaily.com

Apr 19, 2025

Apr 19, 2025

Q1 Earnings Estimate for TVTX Issued By Wedbush - Defense World

Apr 19, 2025

Apr 17, 2025

Geode Capital Management LLC Raises Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Apr 17, 2025

Apr 17, 2025

Franklin Resources Inc. Acquires New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Apr 17, 2025

Apr 15, 2025

Wellington Management Group LLP Makes New $583,000 Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Apr 15, 2025

Apr 15, 2025

Travere Therapeutics (NASDAQ:TVTX) Given “Buy” Rating at Guggenheim - Defense World

Apr 15, 2025

Apr 14, 2025

Travere therapeutics CFO Cline sells $630 in shares By Investing.com - Investing.com India

Apr 14, 2025

Apr 14, 2025

Travere therapeutics CFO Cline sells $630 in shares - Investing.com

Apr 14, 2025

Apr 13, 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2025 - BioSpace

Apr 13, 2025

Apr 12, 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News - GuruFocus

Apr 12, 2025

Apr 12, 2025

Travere Therapeutics price target lowered to $30 from $32 at Scotiabank - Yahoo Finance

Apr 12, 2025

Apr 12, 2025

Scotiabank Updates Price Target for Travere Therapeutics (TVTX) Amid Drug Data Release | TVTX Stock News - GuruFocus

Apr 12, 2025

Apr 11, 2025

Revenues Working Against Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Following 26% Dive - simplywall.st

Apr 11, 2025

Apr 11, 2025

Scotiabank Remains a Buy on Travere Therapeutics (TVTX) - The Globe and Mail

Apr 11, 2025

Apr 11, 2025

Canaccord Increases Price Target for Travere Therapeutics (TVTX) to $47 | TVTX Stock News - GuruFocus

Apr 11, 2025

Apr 10, 2025

Canaccord raises Travere stock target to $47, maintains Buy rating By Investing.com - Investing.com Canada

Apr 10, 2025

Apr 10, 2025

Canaccord raises Travere stock target to $47, maintains Buy rating - Investing.com

Apr 10, 2025

Apr 09, 2025

Retrophin, Inc. entered into an agreement to acquire Desert Gateway, Inc. from Rosetta Granite, Inc. and other shareholders in a reverse merger transaction. - MarketScreener

Apr 09, 2025

Apr 09, 2025

Travere Therapeutics (TVTX) Receives a Buy from Wells Fargo - The Globe and Mail

Apr 09, 2025

Apr 07, 2025

Focal Segmental Glomerulosclerosis Pipeline Analysis - openPR.com

Apr 07, 2025

Apr 03, 2025

Novartis Has A Slight Edge On Travere — Why Analysts Aren't Worried - MSN

Apr 03, 2025

Apr 03, 2025

Cantor Fitzgerald stays bullish on Travere Therapeutics stock By Investing.com - Investing.com UK

Apr 03, 2025

Apr 03, 2025

Trading (TVTX) With Integrated Risk Controls - news.stocktradersdaily.com

Apr 03, 2025

Apr 02, 2025

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $31.00 at Bank of America - Defense World

Apr 02, 2025

Apr 01, 2025

The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts - Benzinga

Apr 01, 2025

Mar 31, 2025

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 - BioSpace

Mar 31, 2025

Mar 26, 2025

Is Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey

Mar 26, 2025

Mar 26, 2025

10 Best Small-Cap Stocks to Buy Before They Explode - Insider Monkey

Mar 26, 2025

Mar 26, 2025

Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights - Yahoo Finance

Mar 26, 2025

Mar 23, 2025

When (TVTX) Moves Investors should Listen - news.stocktradersdaily.com

Mar 23, 2025

Mar 18, 2025

Travere seeks FDA approval for potential FSGS treatment By Investing.com - Investing.com Australia

Mar 18, 2025

Mar 17, 2025

Travere rises on co's marketing application for kidney disease drug - TradingView

Mar 17, 2025

Mar 17, 2025

Travere seeks FDA approval for potential FSGS treatment - Investing.com India

Mar 17, 2025

Mar 17, 2025

Travere Therapeutics Submits sNDA To FDA For Approval Of Filspari (Sparsentan) For The Treatment Of FSGS - Marketscreener.com

Mar 17, 2025

Mar 17, 2025

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS - The Manila Times

Mar 17, 2025

Mar 17, 2025

Travere Therapeutics Submits sNDA for FILSPARI as Potential First FDA-Approved Treatment for FSGS - Nasdaq

Mar 17, 2025

Mar 17, 2025

Breakthrough: First-Ever FSGS Treatment Could Get FDA Green LightFILSPARI Shows Superior Results - StockTitan

Mar 17, 2025

Mar 14, 2025

High Growth Tech Stocks In The US With Promising Potential - Simply Wall St

Mar 14, 2025

Mar 12, 2025

US Bancorp DE Has $554,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Mar 12, 2025

Mar 12, 2025

Travere Therapeutics Expands Team with 77,200 Shares in Strategic Equity Grants - Stock Titan

Mar 12, 2025

Mar 11, 2025

Travere Therapeutics at Leerink Conference: Filspari’s Promising Path - Investing.com

Mar 11, 2025

Mar 11, 2025

Focal Segmental Glomerulosclerosis Treatment Market Size - openPR

Mar 11, 2025

Mar 11, 2025

Is Eli Lilly Stock a Buy? - The Globe and Mail

Mar 11, 2025

Mar 09, 2025

Why Travere Therapeutics Inc. (TVTX) Went Up On Tuesday? - MSN

Mar 09, 2025

Mar 08, 2025

What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings - GuruFocus.com

Mar 08, 2025

Mar 07, 2025

Travere Therapeutics: Tricky Outlook Gives Me Pause For ThoughtDowngrade - Seeking Alpha

Mar 07, 2025